Amy Sing - Bio Path Independent Director
| BPTH Stock | USD 4.20 0.96 29.63% |
Director
Dr. Amy P. Sing, M.D. is an Independent Director of the Company. Dr. Sing has served as a director of BioPath since November 2014. She served as the Senior Medical Director for US Medical Affairs from January 2011 until August 2016 at Genomic Health, Inc., a leading publicly held biotechnology company that assists physicians and patients in making personalized cancer treatment decisions. From 2004 to 2006, Dr. Sing led oversight of the approved breast cancer drug Avastin Investigator Sponsored Trials program at Genentech, Inc., a public biotechnology firm providing major contributions to the understanding and development of cancer research. From 2004 to 2011, Dr. Sing worked in various other leadership and research positions at Genentech, Inc. Dr. Sing also led research teams for Seattle Genetics, Inc. from 1999 to 2003 and has received awards from the National Cancer Institute, American Cancer Society and Stanford University since 2014.
| Age | 57 |
| Tenure | 10 years |
| Address | 4710 Bellaire Boulevard, Bellaire, TX, United States, 77401 |
| Phone | 832 742 1357 |
| Web | https://www.biopathholdings.com |
Bio Path Management Efficiency
The company has return on total asset (ROA) of (1.0319) % which means that it has lost $1.0319 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2002) %, meaning that it created substantial loss on money invested by shareholders. Bio Path's management efficiency ratios could be used to measure how well Bio Path manages its routine affairs as well as how well it operates its assets and liabilities. The Bio Path's current Return On Tangible Assets is estimated to increase to -4.74. The Bio Path's current Return On Capital Employed is estimated to increase to -11.45. As of now, Bio Path's Net Tangible Assets are increasing as compared to previous years.Similar Executives
| Found 1 records | DIRECTOR Age | ||
| Yan MBA | Adagene | 49 | |
Management Performance
| Return On Equity | -2.2 | ||||
| Return On Asset | -1.03 |
Bio Path Holdings Leadership Team
Elected by the shareholders, the Bio Path's board of directors comprises two types of representatives: Bio Path inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Path's management team and ensure that shareholders' interests are well served. Bio Path's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Path's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan MacKenzie, Consultant | ||
| Thomas Walker, Consultant | ||
| Michael MBA, VP Operations | ||
| Peter MBA, Chairman, CoFounder | ||
| Jeffery MD, Consultant | ||
| Anthony Price, Accounting Finance | ||
| Mark Colonnese, Independent Director | ||
| Ulrich Mueller, COO and Secretary | ||
| Heath Cleaver, Director | ||
| Peter Nielsen, Chairman of the Board and Presidentident, CEO, CFO, Treasurer | ||
| MBA Ashizawa, Development Research | ||
| Paul Aubert, Independent Director | ||
| Victoria Rac, Regulatory Consultant | ||
| Douglas Morris, Co-Founder and Director | ||
| Amy Sing, Independent Director | ||
| Michael Garrison, Independent Director |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio Path a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.2 | ||||
| Return On Asset | -1.03 | ||||
| Current Valuation | 1.91 M | ||||
| Shares Outstanding | 753.79 K | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 3.72 % | ||||
| Number Of Shares Shorted | 67.41 K | ||||
| Price To Earning | (6.21) X | ||||
| Price To Book | 5.21 X | ||||
| EBITDA | (15.66 M) |
Pair Trading with Bio Path
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Path position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Path will appreciate offsetting losses from the drop in the long position's value.Moving against Bio Stock
| 0.81 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.66 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.61 | ZNTL | Zentalis PharmaceuticalsL Financial Report 8th of May 2024 | PairCorr |
| 0.53 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.51 | JSPRW | Jasper Therapeutics | PairCorr |
The ability to find closely correlated positions to Bio Path could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Path when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Path - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Path Holdings to buy it.
The correlation of Bio Path is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Path moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Path Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Path can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Bio Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Bio Path's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (33.63) | Return On Assets (1.03) | Return On Equity (2.20) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.